當(dāng)前位置:武漢普諾賽生命科技有限公司>>技術(shù)文章>>SH-SY5Y [SHSY-5Y] (人神經(jīng)母細(xì)胞瘤細(xì)胞):滿足特殊實驗設(shè)計與應(yīng)用需求
SH-SY5Y [SHSY-5Y] (人神經(jīng)母細(xì)胞瘤細(xì)胞):滿足特殊實驗設(shè)計與應(yīng)用需求
SH-SY5Y細(xì)胞是于1970年建自骨瘤轉(zhuǎn)移灶的神經(jīng)母細(xì)胞瘤SK-N-SH細(xì)胞系經(jīng)3次克隆后的亞系(SK-N-SH→SH-SY→SH-SY5→SH-SY5Y)。SH-SY5Y細(xì)胞顯示中等水平的多巴胺-β-羥基酶活性,SH-SY5Y細(xì)胞的飽和密度大于1×10^6Cells/Vial×2Vials
別稱:SHSY5Y;SHSY-5Y;SH-Sy5y;SK-SH-SY5Y;SY5Y
種屬:人
生長特性:貼壁細(xì)胞,極少量懸浮
細(xì)胞形態(tài):上皮細(xì)胞樣
凍存條件:凍存液:90% FBS+10% DMSO;溫度:液氮
培養(yǎng)方案A(默認(rèn)):生長培養(yǎng)基:SH-SY5Y [SHSY-5Y]細(xì)胞專用培養(yǎng)基
培養(yǎng)條件:氣相:空氣,95%;CO?,5%, 溫度:37℃
推薦傳代比例:1:3-1:8
推薦換液頻率:2-3次/周
組織來源:腦神經(jīng)母細(xì)胞瘤,轉(zhuǎn)移部位骨髓
細(xì)胞類型:腫瘤細(xì)胞
腫瘤類型:神經(jīng)母細(xì)胞瘤細(xì)胞
生物安全等級:BSL-1
保藏機構(gòu):ATCC; CRL-2266 DSMZ; ACC-209 ECACC; 94030304
SH-SY5Y [SHSY-5Y]人神經(jīng)母細(xì)胞瘤細(xì)胞注意事項
1.該細(xì)胞容易聚團,傳代第二天輕微聚團甚至漂浮為正常現(xiàn)象,無需換液繼續(xù)培養(yǎng)2-3天后細(xì)胞可正常貼壁。
2.細(xì)胞聚團嚴(yán)重影響細(xì)胞生長后,可用胰酶消化細(xì)胞使之重新分散,傳代后少動少換液,聚團會有改善。
SH-SY5Y [SHSY-5Y]人神經(jīng)母細(xì)胞瘤細(xì)胞引用文獻
Targeted Ganglion Delivery of CaV2.2-Mediated Peptide by DNA Nanoflowers for Relieving Myocardial Infarction and Neuropathic Pain(2025)
期刊:ACS Nano
DOI:10.1021/acsnano.4c17325
影響因子:15.8
引用產(chǎn)品: SH-SY5Y [SHSY-5Y] 細(xì)胞, 293T [HEK-293T] 細(xì)胞
Traditional Chinese Medicine Borneol-Based Polymeric Micelles Intracerebral Drug Delivery System for Precisely Pathogenesis-Adaptive Treatment of Ischemic Stroke(2025)
期刊:Advanced Science
DOI:10.1002/advs.202410889
影響因子:14.3
引用產(chǎn)品: BV2 細(xì)胞, bEnd.3 [BEND3] 細(xì)胞, SH-SY5Y [SHSY-5Y] 細(xì)胞
CKLF1 disrupts microglial efferocytosis following acute ischemic stroke by binding to phosphatidylserine(2025)
期刊:CELL DEATH AND DIFFERENTIATION
DOI:10.1038/s41418-025-01475-x
影響因子:13.7
引用產(chǎn)品: BV2 細(xì)胞, SH-SY5Y [SHSY-5Y] 細(xì)胞